Dyadic International (NASDAQ:DYAI) Stock Passes Above 50 Day Moving Average – Should You Sell?

Dyadic International, Inc. (NASDAQ:DYAI)’s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.56 and traded as high as $1.99. Dyadic International shares last traded at $1.73, with a volume of 171,662 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a research note on Thursday, November 14th.

Dyadic International Trading Down 11.1 %

The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. The stock has a market capitalization of $51.04 million, a P/E ratio of -7.50 and a beta of 0.89. The company has a fifty day simple moving average of $1.56 and a two-hundred day simple moving average of $1.39.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.06. The business had revenue of $1.96 million during the quarter, compared to analyst estimates of $1.05 million. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. During the same period in the previous year, the firm earned ($0.06) EPS. On average, sell-side analysts expect that Dyadic International, Inc. will post -0.18 earnings per share for the current year.

Institutional Trading of Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. boosted its holdings in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.97% of Dyadic International worth $903,000 as of its most recent filing with the Securities and Exchange Commission. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.